SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from NANOVIRICIDES, INC. (NNVC) (CIK 0001379006) (NNVC) — May 30, 2012

NANOVIRICIDES, INC. (NNVC) (CIK 0001379006)
Date: May 30, 2012 · CIK: 0001379006 · Accession: 0001144204-12-032614

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 000-52318

Date
May 30, 2012
Author
Chief Accountant
Form
CORRESP
Company
NANOVIRICIDES, INC. (NNVC) (CIK 0001379006)

Letter

VIA EDGAR United States Securities and Exchange Commission Attention: Jim B. Rosenberg, Form 10-K for the Fiscal Year Ended June 30, 2011 Filed October 13, 2011 File No. 000-52318

Re: NanoViricides, Inc.

Dear Mr. Rosenberg,

The purpose of this correspondence is to respectfully request an additional ten day extension to reply to the comments of the staff of the U.S. Securities and Exchange Commission (the “Commission”) provided in a telephone conversation with the Commission on May 11, 2012.

Should you have any questions or require any further information, please do not hesitate to contact us.

Very truly yours,
/s/ Eugene Seymour

Show Raw Text
CORRESP
1
filename1.htm

May 30, 2012

VIA EDGAR

United States Securities and Exchange Commission

Mail Stop 4720

Washington, D.C. 20549

Attention:      Jim B. Rosenberg,

Senior Assistant
Chief Accountant

    Re:
    NanoViricides, Inc.

    Form 10-K for the Fiscal Year Ended June 30, 2011

Filed October 13, 2011

File No. 000-52318

Dear Mr. Rosenberg,

The purpose of this
correspondence is to respectfully request an additional ten day extension to reply to the comments of the staff of the U.S. Securities
and Exchange Commission (the “Commission”) provided in a telephone conversation with the
Commission on May 11, 2012.

Should you have any
questions or require any further information, please do not hesitate to contact us.

Very truly yours,

/s/ Eugene Seymour

Eugene Seymour, MD, MPH,

Chief Executive Officer

PC/mm